Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Burger, Jan A., Landau, Dan A., Taylor-Weiner, Amaro, Bozic, Ivana, Zhang, Huidan, Sarosiek, Kristopher, Wang, Lili, Stewart, Chip, Fan, Jean, Hoellenriegel, Julia, Sivina, Mariela, Dubuc, Adrian M., Fraser, Cameron, Han, Yulong, Li, Shuqiang, Livak, Kenneth J., Zou, Lihua, Wan, Youzhong, Konoplev, Sergej, Sougnez, Carrie, Brown, Jennifer R., Abruzzo, Lynne V., Carter, Scott L., Keating, Michael J., Davids, Matthew S., Wierda, William G., Cibulskis, Kristian, Zenz, Thorsten, Werner, Lillian, Cin, Paola Dal, Kharchencko, Peter, Neuberg, Donna, Kantarjian, Hagop, Lander, Eric, Gabriel, Stacey, O'Brien, Susan, Letai, Anthony, Weitz, David A., Nowak, Martin A., Getz, Gad, Wu, Catherine J.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876453/
https://ncbi.nlm.nih.gov/pubmed/27199251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms11589
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados